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This study describes the development and validation of a gas
chromatography–mass spectrometry (GC–MS) method to identify
and quantitate phenytoin in brain microdialysate, saliva and blood
from human samples.
A solid-phase extraction (SPE) was performed with a nonpolar C8-
SCX column. The eluate was evaporated with nitrogen (508C) and
derivatized with trimethylsulfonium hydroxide before GC–MS ana-
lysis. As the internal standard, 5-(p-methylphenyl)-5-phenylhydantoin
was used. The MS was run in scan mode and the identification was
made with three ion fragment masses. All peaks were identified with
MassLib. Spiked phenytoin samples showed recovery after SPE of
94%. The calibration curve (phenytoin 50 to 1,200 ng/mL, n5 6, at
six concentration levels) showed good linearity and correlation (r2 >
0.998). The limit of detection was 15 ng/mL; the limit of quantification
was 50 ng/mL. Dried extracted samples were stable within a 15% de-
viation range for 4 weeks at room temperature. The method met
International Organization for Standardization standards and was able
to detect and quantify phenytoin in different biological matrices and
patient samples. The GC–MS method with SPE is specific, sensitive,
robust and well reproducible, and is therefore an appropriate candi-
date for the pharmacokinetic assessment of phenytoin concentrations
in different human biological samples.
Introduction
Epilepsy is a disorder of the central neural system characterized
by recurrent unprovoked seizures caused by excessive dis-
charge of electrical activity (1). Epilepsy can be treated with
different antiepileptic drugs that generally render 80% of
newly diagnosed patients seizure-free (2). Phenytoin (PHT)
[C15H12N2O2 (3); molecular weight: 252.3 (3)] is a well-
established antiepileptic drug designed to prevent and treat sei-
zures (4). It is routinely used on neurosurgical intensive care
unit patients with brain injuries.
PHT has a small therapeutic index; its therapeutic concentra-
tion range in blood serum is 10–20 mg/L (40–80 mmol/L) (5)
for adults and children older than 3 months. Ingestion of more
than 20 mg/kg in humans [normal oral dosage for adults is
6 mg/kg (5)] usually results in clinical toxicity (6). PHT can
produce signiﬁcant dose-related toxicity because of its
complex pharmacokinetics (PK). The limited therapeutic
index, combined with the large inter-individual variability of
metabolism [half life 16–60 h, depending on plasma levels
(7, 8)], and the nonlinear pharmacokinetics of PHT (9, 10)
highlight the importance of therapeutic drug monitoring
(TDM). On the other hand, relatively few studies have been
able to demonstrate the beneﬁts of TDM of antiepileptic drugs
(11). However, therapeutic monitoring of PHT using Bayesian
forecasting was successfully applied to rapidly achieve thera-
peutic plasma levels using an easy-to-apply PHT loading dose
regimen in a hospital setting (12).
The monitoring of brain tissue biochemistry during intensive
care cerebral microdialysis is well established (13). Samples
generated by brain microdialysis have the potential to correlate
PHT concentrations at the site of action, with plasma values
mostly used for TDM (14, 15).
The correlation of toxicity and plasma level concentration is
well established. However, the PK in critically ill patients, and
its potential change related to the characteristics of the blood-
brain barrier, contribute to the lack of understanding of the
kinetics and mode of action of antiepileptics in the brain. The
correlation between PK in blood and the target tissue in brain
is not established. To investigate correlations of PHT concentra-
tion in blood plasma, saliva (oral ﬂuid) and tissue microdialy-
sate, a sensitive and speciﬁc analytical method is needed
(16, 17). Saliva has been shown to serve as an alternative
sample to blood plasma for TDM (18).
Commonly used analytical methods without mass spectrom-
etry (MS) detection do not reach the sensitivity needed to quanti-
tate the free fraction of PHT and the low biological PHT
concentrations (19). For clinical trials, a validated method is
required by authorities such as the Food and Drug Administration
(FDA). Gas chromatography (GC) with MS is effective and specif-
ic to separately analyze parent PHT and its metabolites (20).
However, current published GC–MS methods are not accurate
and sensitive enough to identify and quantify the expected low
levels of PHT in microdialysate samples from the human brain.
Also, the high sample volume of 500 mL used in a recently pub-
lished study is far too large for the usual microdialysis sampling in
patients, with a 2 mL/min ﬂow rate, and therefore not appropriate
for TDM (21). GC–MS analysis needs an extraction step such as
solid-phase extraction (SPE) to clean the sample and to eliminate
interfering biological matrix materials like proteins and lipids
prior to injection into the GC–MS system. Furthermore, to detect
PHT with sufﬁcient sensitivity by GC–MS, a derivatization of PHT
is necessary (22, 23). A structural analogue to PHT (C16H14N2O2;
molecular weight: 266.3), 5-(p-methylphenyl)-5-phenylhydantoin
(MPPH), is chosen as an internal standard (IS) (24).
The aim of the present analytical study was to establish a se-
lective and sensitive GC–MS method allowing the determin-
ation of PHT in different human biological samples, especially
in brain microdialysates. The analytical method should cover a
therapeutic range of free PHT concentration ranging from 50 to
1,200 ng/mL. A further objective of this study was to develop a
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simple and effective sample extraction method, which can be
used for different biological matrices like blood, dialysate or
saliva to reproducibly provide stable, reliable and clean analytes
for GC–MS analysis. The suitability of the analytical GC–MS
method has to be demonstrated by validation according to
International Organization for Standardization (ISO) 17025 to
be used in corresponding investigations with samples from
patients (clinical trials). The resulting analytical method is a
prerequisite for further PK and pharmacodynamic (PD)
investigations.
Material and Methods
Chemicals and samples
The PHT reference was purchased from Desitin Pharma GmbH
(Liestal, Switzerland) and from the European Pharmacopoeia
(Strasbourg, France). The IS, MPPH (C16H14N2O2; molecular
weight¼ 266.29), purity .99% was purchased from
Sigma-Aldrich Chemie (Steinheim, Germany). Calcium chloride,
citric acid monohydrate, potassium chloride, magnesium chlor-
ide hexahydrate, sodium chloride and sodium hydroxide and the
solvents methanol (MeOH), acetic acid (100%) and acetone
were of analytical grade and purchased from Merck (Darmstadt,
Germany). Trimethylsulfonium hydroxide (TMSH), 0.2M in
MeOH for derivatization, was purchased from Macherey-Nagel
(Oensingen, Switzerland). Nitrogen (analytical grade) for extract
drying, and helium (analytical grade) for GC, were obtained
from Carbagas (Liebefeld, Switzerland).
Artiﬁcial cerebrospinal ﬂuid (aCSF), composed of 8.59 g NaCl,
0.2013 g KCl, 0.1332 g CaCl2 and 0.1758 g MgCl2  6(H2O), was
prepared according to the pre-clinical device company CMA
(Stockholm, Sweden; dialysate solution) (25). CPDA-1 blood (an
anticoagulant citrate phosphate dextrose adenine solution; sub-
sequently referred to as blood plasma) was obtained from the
Blood Donor Center in Bern, Switzerland. Saliva was provided by
a volunteer. Ex situ brain tumor tissue, which had been surgically
removed from patients treated with PHT, was dialyzed against
aCSF with a ﬂow rate of 2 mL min, yielding a sample of approxi-
mately 60 mL. Approximately 2 mL of patient CPDA-1 blood
samples with PHT were collected. Both samples (dialysates
and CPDA-1 blood) were provided by the Department of
Neurosurgery (Kantonsspital Aarau AG, Switzerland). The sam-
pling procedure was presented to the ethical committee of the
Kantonsspital Aarau, which did not require formal ethical ap-
proval because the dialysates were made ex situ. All biological
samples (CPDA-1 blood plasma and dialysate) were frozen im-
mediately after sampling at –248C. For transportation, a refriger-
ation chain (–20+28C) was guaranteed. Before extraction and
analysis, the samples were thawed at room temperature for
30 min and then vortexed for 1 min.
IS, calibrator standard solutions, quality controls,
system suitability test and sample preparation
MPPH (IS) 1 mg/mL in MeOH was prepared as a stock solution
and stored at 2–88C. This stock solution was diluted with
MeOH to 100 ng/mL for addition to solutions [internal standard
solution (ISS), 100 ng/mL]. The PHT reference stock solution
containing 1 mg PHT/mL MeOH was stored at 2–88C. To obtain
calibration standard solutions (Cals) of 1,200 (Cal 6), 1,000 (Cal
5), 800 (Cal 4), 300 (Cal 3), 150 (Cal 2) and 50 ng/mL (Cal 1),
the stock solution was diluted freshly each time with MeOH for
each measurement. To each calibrator standard (Cal), 1,200 ng/
mL MPPH (12 mL ISS) was added as IS. To each Cal, 1 mL of
biological matrix (aCSF, blood plasma or saliva) was added for
validation purposes. For quality control (QC), solutions were
prepared with 100 ng/mL (QC 1) and 1,000 ng/mL (QC 2)
PHT, also containing 1,200 ng/mL MPPH (12 mL ISS) as IS and
1 mL of blood plasma, aCSF or saliva matrix. The system suitabil-
ity test (SST) was prepared with the PHT reference solution and
IS, to a ﬁnal probe of 100 ng/mL PHT and 1,200 ng/mL MPPH
(12 mL ISS).
Samples from patients were included to test the method in
real biological probes. PHT-containing microdialysis samples
(volume of 50 mL) from six patients (requiring approximately
25 min of collection time) were added to 450 mL aCSF and
1,200 ng MPPH (12 mL ISS) as IS prior to extraction. Blood
plasma samples (volume of 500 mL) from PHT-treated patients
were spiked with 1,200 ng MPPH (12 mL ISS) as IS. The
volumes of dialysate and blood were not identical to the
volumes used in the validation procedure; however, they were
useful for comparing artiﬁcial and real samples.
SPE procedure
For SPE, cartridges were used with nonpolar C8 sorbent and a
strong cation exchanger (SCX) (Bond Elute LRC Certify,
130MG; Varian). The extraction procedure is shown in Figure 1.
The method was adapted from literature (26). After equilibration
of the SPE columns with 1 mL acetonitrile for approximately
2 min, the pH was adjusted with 1 mL citric buffer, pH 5.0
(20.1 g/L citric acid, 8.0 g/L NaOH plus pH adjustment with
1 M HCl) (27). The calibrators (1 mL), QCs (1 mL) and samples
(0.5 mL) were applied to the SPE columns (Figure 1). The SPE
columns were washed with 1 mL citric buffer, followed by 1 mL
of 0.01 M acetic acid for pH adjustment (pH 3.5). After appli-
cation of a vacuum (approximately 0.5 bar) and drying for 5 min
(using a vacuum pump; Vac Master KNF LAB Laboport), PHT
was eluted with 2  1 mL acetone. The columns were vacuum-
dried again for 1 min at 0.5 bar. The eluate was transferred into
a 2 mL vial and evaporated with nitrogen at 508C. The reconsti-
tution and derivatization were performed with 50 mL TMSH
immediately before GC–MS analysis at room temperature and
vortexed for 10 s (22, 28, 29).
GC–MS analysis
To demonstrate the robustness of the developed method, two
different GC–MS systems available in the same lab were used.
An HP5890 gas chromatograph was used, connected to an
HP5971 mass selective detector (with Chemstation software
supplied by Hewlett Packard). The backup system was an
Agilent 6890N/5973 Inert GC–MS. An autosampler and an in-
jector were connected to both systems (Agilent 7673 with an in-
jection syringe of 10 mL volume). Two microliters of the
prepared samples were injected to the liner prior to the GC
column. The GC column was a polysiloxane Agilent J&W
Capillary 122-5532, DB-5MS, length, 30 m; i.d., 0.250 mm; ﬁlm,
0.25 mm; for temperatures from –60 to 3508C. The temperature
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program was set to 1208C for 1 min, then raised by 108C/min to
3008C and held for 6 min. The carrier gas was 99.95% high
purity helium with a ﬂow of 1.6 mL per min. The MS systems
were on scan mode to additionally check for interfering materi-
als. The temperature of the MS detector was 1508C. The settings
for the ion source and the transfer line were 230 and 2808C, re-
spectively. The scan range was between 50 and 650 amu. The
reference window for the data analysis parameters for PHT was
2 min, with a non-reference window of 1 min. All chromato-
graphic peaks were analyzed with MassLib (www.masslib.com),
allowing mass spectra identiﬁcation by both similarity and
identity. The search algorithm Search for Similar and
Identical Compounds (SISCOM) originates from Henneberg,
Weimann, and Ziegler (Max-Planck-Institute, Mu¨hlheim a.d.
Ruhr, Germany) and was developed in the 1970s (30).
Validation procedure
The validation according to ISO 17025 includes the assessment
of selectivity, accuracy, recovery of PHT after SPE, reproducibil-
ity, suitability of the calibration curves, stability of PHT and
matrix effects. Indicators for the sensitivity of the method
were the accurate assignment of the ions in different matrices
and the limit of detection (LOD) and limit of quantiﬁcation
(LOQ). Blank samples from six different sources were used to
demonstrate selectivity.
Furthermore, the selectivity of the method was determined
by using the selected GC column combined with an MS detect-
or. The selectivity was veriﬁed based on the retention time and
the allocation of one quantiﬁer ion and two qualiﬁer ions. The
accuracy was tested at the same levels as the calibrators and
with two additional levels at QC 1 (100 ng/mL) and QC 2
(1,000 ng/mL) (n ¼ 6). Two different solutions (prepared from
different stock solutions) were used to prepare the calibration
and QC samples. The recovery of PHT was analyzed by measure-
ment of QC 1 (100 ng/mL) and QC 2 (1,000 ng/mL) (n ¼ 3),
with QC 1 (100 ng/mL) and QC 2 (1,000 ng/mL) (n ¼ 3)
without SPE. The reproducibility and suitability of calibration
curves was measured by 2  3 complete series of Cal 1 to Cal 6
samples, including the extraction step. Inter-assay percent rela-
tive standard deviation (RSD), linearity and regression coefﬁcient
were calculated. PHT stability was analyzed with QC 1 samples
after extraction for both non-derivatized [5 weeks at room
temperature (n ¼ 10)] and derivatized samples (33 h without
speciﬁc cooling). Matrix effects were analyzed by comparing the
calibration curves generated with the three matrices: aCSF
(n ¼ 6 series), blood (n ¼ 3 series) and saliva (n ¼ 3 series).
Thus, the values of each calibrator and matrix were also
compared.
Statistical methods
The statistical data were calculated with Microsoft Excel and
PASW Statistics 18.0. To show the similarity between the differ-
ent matrices, a one-way analysis of variance (ANOVA) was used.
Furthermore, for each matrix, the six calibrator levels were
checked with t-tests to determine whether the measured
values differed signiﬁcantly within each level.
Results and Discussion
GC–MS analysis of PHT (separation and identiﬁcation
of PHT and MPPH), retention time, ion fragment mass,
LOD and LOQ
PHT and MPPH have different, but comparable, retention times
consistent with their chemical characteristics. The GC-MS
chromatogram of PHT showed a retention time (RT) of
15.12 min and the IS has an RT of 16.15 min. The relative RT
was 1:1.015. The suitability of MPPH as IS for GC–MS analysis
of PHT was further supported by the chromatogram (Figure 2).
The observed molecular fragment masses were [280, 203, 194,
118] for PHT and [294, 203, 194, 118] for MPPH. These
minimal differences in the RT, and the comparable molecular
fragment mass spectra, illustrate the strong similarity between
the analyte PHT and the IS, MPPH. The calculation of the
sample concentration was made only with the ion fragment
masses that were identiﬁed for PHT and MPPH.
The MassLib system could easily detect PHT and MPPH sep-
arately by their mass chromatogram differences. Because of the
independence of the data type and the format of the analyte,
MassLib has been successfully used in earlier GC–MS studies,
and is now widely used as a standard to identify chemical sub-
stances in toxicology (31). Also, these results were in line with
prior studies and conﬁrmed the suitability of this tool for the
GC–MS analytical method to identify and quantify PHT.
The LOD was calculated as signal to blank noise ratio (S/N)
(.3:1). The LOD for this method in aCSF, saliva and blood was
15 ng/mL, according to the FDA guidelines or Deutsches
Institut fu¨r Normung (DIN) standards (32, 33). Following the
Figure 1. Schematic sample process: generation of the three sample matrices,
processing during SPE and derivatization prior to GC–MS measurement.
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FDA guidelines, the LOQ was 50 ng/mL PHT and calculated as
ﬁve times the response/blank noise. Thus, the LOQ was reached
at Cal 1 level (50 ng/mL PHT). This also corresponds to the FDA
guidelines, claiming 20% reproducibility at the LOQ level (32,
33), which was reached with Cal 1.
Accuracy of the calibrators, repeatability precision
and laboratory precision
For assessment of the accuracy, the calibrators and QCs of six
individual measurements (n ¼ 6) were performed. The accur-
acy was tested with two non-identical solutions, the stock solu-
tions for calibration and the one for QC samples. The results of
the one-way ANOVA showed no signiﬁcant differences for all
matrices (F ¼ 0.0002; p ¼ 0.9998). In the target range of thera-
peutic PHT concentrations in microdialysates (.50 ng/mL,
,1,200 ng/mL), accuracy was between 104.6 and 98.9%. As
expected, the largest deviation was observed at the LOQ and at
the lowest concentration level (Cal 1 at 50 ng/mL) of the cali-
bration curve, showing an accuracy value of 104.6% (Table I).
The calibrator values showed minimum and maximum percent
deviations of 20% in Cal 1, 7% in Cal 2, 3% in Cal 3, 1% in Cal
4, 9% in Cal 5, 6% in Cal 6, 12% in QC1 and 6% in QC2
(Table I). Statistically, the deviations of each concentration
value did not differ for the entire calibration, demonstrating
that there were no outliers. All of the values were within the
maximum allowed bias of 15% (32). Repeatability precision
(inter-assay variability), the minimum and maximum deviation
of all levels of measurements, was within 15% of the coefﬁcient
of variation (CV) (Table I).
Regarding laboratory precision (intra-assay variability), for
the QC 1 and QC 2 measurements (n ¼ 6), the mean percent
deviation from the target value was 2.7% for QC 1 (100 ng/mL)
and 0.6% for QC 2 (1,000 ng/mL). As with the calibrators, the
QC 1 and QC 2 also showed a deviation from the nominal
value of less than 15% CV. These results support the robustness
of the method. Neither the operator nor the day of preparation
inﬂuenced the results in a detectable manner. There was no
difference in the characteristics of the chromatogram when
changing from the GC–MS HP system to the backup (Agilent
Systems). The laboratory in which the investigations were
made is part of the forensic laboratories in Switzerland and
takes part in all necessary proﬁciency tests to be ISO 17025
certiﬁed.
Linearity and regression coefﬁcient of calibration curve
The linearity of the calibration was tested with replicates of Cal
samples for the PHT concentration range of 50 to 1,200 ng/mL
in aCSF (n ¼ 6), saliva (n ¼ 3) and blood (n ¼ 3). As shown in
Table I, the calibration curve for PHT showed a linear regres-
sion coefﬁcient (r2) greater than 0.998 (r2blood plasma ¼ 0.998,
r2dialysate ¼ 0.999 and r2saliva ¼ 0.999) in all three matrices, indi-
cating excellent linearity in the target concentrations (Table I).
The calculations, including the linearity check of the calibra-
tion curves, were directly conducted by the ChemStation
software.
The one-way ANOVA showed no statistically signiﬁcant differ-
ences in calibrator-spiked samples of the different matrices: F ¼
0.0002, p ¼ 0.999. Each calibrator level was tested for consist-
ency using a t-test. The t-test showed no statistically signiﬁcant
deviation at each calibration level. This allows for the validation
procedure to be simpliﬁed by analyzing only one matrix and ex-
trapolating the results to the other matrices. It is standard that
the deviation of the lowest Cal from the nominal value should
be within +20%. For all other Cals, the deviation from the
nominal value should be within +15%, as required by FDA
Figure 2. Total ion chromatograms (TICs) and MS fragment spectra of PHT (50 ng/mL) and MPPH (1,200 ng/mL). GC–MS chromatograms: (A) PHT; (B) IS MPPH; (C) MS
fragments and a 2.0 mL injection of a 50 ng/mL PHT solution LOQ; (D) time-related peaks and 1,200 ng/mL MPPH. (A) The ion fragments for PHT are [280,203,194,118], (C)
RI33: TIC chromatogram; chromatograms of the mass fragments at m/z 280, 203 and 194 and (B) for MPPH the fragments are [294,203,194,118], (D) RI33: TIC chromatogram;
chromatograms of the mass fragments at m/z 294, 217 and 208.
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Table I
Calculated Data from the Measurements with aCSF as Matrix and Arithmetic Mean of the Calibrators in Different Matrices*
Calculated data from the measurements with aCSF as matrix
Sample name Overall mean SD Mean deviation (%) Inter-assay CV
(%)
Accuracy
(%)
Cal 1 (50 ng/mL) 52.3 6 9.65 11.5 104.6
Cal 2 (150 ng/mL) 152.5 16.9 7.51 11.1 101.7
Cal 3 (300 ng/mL) 296.7 33.3 9.33 11.2 98.9
Cal 4 (600 ng/mL) 597 55 6.75 9.2 99.5
Cal 5 (1,000 ng/mL) 996 48 3.55 4.8 99.6
Cal 6 (1,200 ng/mL) 1,220 65 4.46 5.3 101.7
QC 1 (100 ng/mL) 102.7 6 2.7 6.3 102.7
QC 2 (1,000 ng/mL) 1,005.7 35 0.6 3.6 100.6
Arithmetic mean of the calibrators in different matrices
Calibrator (concentration) aCSF mean/deviation from target concentration
(n ¼ 6)
Saliva mean/deviation from target concentration
(n ¼ 3)
Blood plasma mean deviation from target concentration
(n ¼ 3)
Cal 1 (50 ng) 52.3/20% 42.8/14.4% 42/16.0%
Cal 2 (150 ng) 152.5/7% 153/05.7% 154.6/4.8%
Cal 3 (300 ng) 296.7/3% 287.8/6% 296.8/3.9%
Cal 4 (600 ng) 597/1% 612 /1.9% 627/4.5%
Cal 5 (1,000 ng) 996/9% 998/1.7% 972/6.67%
Cal 6 (1,200 ng) 1,220/6% 1,206/1.1% 1,194/0.7%
Linear best fit aCSF Saliva Blood plasma
Coefficient of determination (r2) 0.999 0.999 0.998
y-intercept 0.288 3.818 5.542
Slope (x) calibration 1.006 1.002 0.989
*Note: All samples were spiked with PHT. Mean deviation (%): mean percent deviation from target, inter–assay; CV (%): inter-assay percent RSD; accuracy (%): accuracy calculated out of each sample group in percent (n ¼ 6 for all samples).
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guidelines (32). The presented method fulﬁlled these require-
ments and even performed superiorly.
SPE; recovery with and without SPE
To produce reproducible GC–MS data from biological samples,
an appropriate clean-up procedure of the samples is necessary
to eliminate the matrix components that may potentially inter-
fere with the analysis, to maintain the responsiveness, and to
keep the method consistent and reliable, even after larger
series of sample analyses. SPE is widely used for the extraction
procedure in GC–MS analyses. SPE columns are commercially
available, which allows high-grade and reproducible quality
characteristics. The mixed-mode silica SPE columns used in
this investigation are also frequently used in forensic toxicol-
ogy to extract basic and cationic drugs, and are also very effect-
ive for the extraction of a wide range of compounds from
aqueous matrices like urine, dialysate or blood (34). They are
appropriate for small sample volumes and low concentrations
of the investigated substances (28, 29), as was the objective
in this study.
A single extraction required 40 min, including the time for
admixing the solvents, equilibration, ﬂow through the sorbent
and drying of the eluate. This indicates that the method is not
intended for routine serial TDM analyses, but fulﬁls the require-
ments for research.
The recovery was analyzed by the measurement of spiked
QC 1 and QC 2 samples extracted in SPE columns, compared
with spiked QC 1 and QC 2 samples without extraction. The
difference between the PHT values of QC 1 and QC 2 with and
without SPE was within an 8% range for QC 1 and 6% for QC
2, which demonstrates the efﬁciency and reliability of the SPE
(n ¼ 3). The inter-assay CVs (%) of the recovery were 15% for
QC1 and 2% for QC2. The recovery of more than 90% of
the spiked samples was consistent and reproducible (n ¼ 6)
and demonstrated that the SPE columns are suitable for the
extraction of PHT from biological samples such as human
blood plasma, saliva or brain microdialysate (32). The amount
of PHT recovered after SPE was 94.1% for 100 ng/mL and
94.3% for 1,000 ng/mL, compared to the amount found in
unextracted QC samples (100%) (n ¼ 3).
Stability of the extracted PHT samples
The stability of the processed samples was tested over time by
preparing and extracting QC 1 10 times. The eluate was evapo-
rated (Figure 1) and the dried QC 1 samples were stored at
room temperature. These samples were derivatized with TMSH
at Weeks 0, 2, 3, 4, and 5 and measured immediately after deri-
vatization. The variations of the measured concentration over
time were within 15%. No signiﬁcant changes, deviation or
trend for degradation were detectable in the GC vials during
storage. This leads to the conclusion that the dried PHT eluate
was highly stable at room temperature and no time-dependent
degradation occurred during the 5 weeks. In practical terms,
these results demonstrate that the processed PHT samples
(cleaned up) are stable and can be stored at room temperature
without loss of PHT before TMSH derivatization for the
GC–MS analyses.
The short time stability testing of derivatized QC samples,
stored without artiﬁcial cooling at ambient temperature of ap-
proximately 308C, performed three times at 0, 23 and 33 h,
showed an even smaller deviation than those in the underiva-
tized study over 5 weeks. The deviations from the ﬁrst meas-
urement were within 4% at 100 ng/mL and 1% at 1,000 ng/mL.
There was also no statistically signiﬁcant decrease in the con-
centrations of PHT or IS over time, demonstrating the stability
of the derivatized samples over at least 24 h at slightly elevated
temperatures (e.g., in a probe tray or autosampler), even when
the vial cap was perforated by the injection needle. The ana-
lysis of the underivatized stored samples after SPE showed at
100 ng/mL a deviation from the ﬁrst measurement within 3%,
and at 1,000 ng/mL a deviation of 5%. The stability data from
the derivatized and non-derivatized groups that were simultan-
eously assessed showed no signiﬁcant variations between the
groups. Therefore, biological PHT probes (after SPE and evapor-
ation) are very stable at room temperature over more than a
month, and are not affected by conditions encountered in an
ordinary analytical lab. No speciﬁc storage precautions are
needed.
Selectivity and speciﬁcity
The selectivity and speciﬁcity were demonstrated in all three
matrices (blood plasma, dialysate and saliva) by good peak dif-
ferentiation and quantiﬁcation of PHT. Both the blank biological
samples without IS and those with IS were negative; hence, any
false positive blank samples could be excluded (aCSF: n ¼ 6;
saliva: n ¼ 3; blood plasma: n ¼ 3).
Samples from patients receiving PHT
To test the method on real human biological samples, ex situ
brain tumor microdialysates and blood samples from six patients
treated with PHT were analyzed. The volumes of dialysate and
blood were not identical to the sample amount in the validation
(described previously). Nevertheless, the ﬁrst indication on the
use of the method was observed in non-spiked biological
samples (patients’ probes). The results of the dialyses samples
were (in ng/mL) 54.8 for Patient 1, 162.6 for Patient 2, 45 for
Patient 3, 63.4 for Patient 4, 353.2 for Patient 5 and 661 for
Patient 6. The corresponding blood values (in ng/mL) were
2,245 for Patient 1, 3,078 for Patient 2, 5,676 for Patient 3,
19,073 for Patient 5 and 16,349 for Patient 6. No blood was avail-
able from Patient 4. The blood and dialysate data from the indi-
vidual patients were consistent. Only 1–5% of blood plasma in
brain ex situ dialysates resulted, which corresponds to approxi-
mately half of the assumed free serum PHT concentration (10%
free PHT in plasma). The measured PHT concentrations were in
the tested range of the method. It has to be speculated that in
the monitored ICU patients, either steady-state conditions
in the brain (deep compartment) were not yet achieved, or
other speciﬁc PK conditions existed, indicating a more compli-
cated extrapolation from plasma to the brain values (blood-
brain-barrier or leaking central compartment). No saliva (oral
ﬂuid) samples were collected and analyzed from patients. The
results show the importance of testing and validating a new
TDM analysis. The need for parameter validation, including
correct modeling of data, is crucial for reliable drug
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concentration tracking in biological materials intended to inves-
tigate PK/PD correlations in such critical patients. Such studies
could result in safer, more efﬁcacious and rational drug dosing
in patients.
Conclusions
The goal of the study was to establish a selective and sensitive
GC–MS method that allows for the determination of PHT in
different biological samples matrices such as blood plasma,
saliva or brain microdialysate for TDM and related PK/PD
investigations.
The robustness of the method was illustrated by using two
different analytical systems, which did not show any differences
in the response and results. There was no deviation between
the measurements made for the calibration curve with different
matrices, and furthermore, the QC of the measurements with
different matrices also showed no differences. The presented
method has been proven for PHT detection and quantiﬁcation
in the aimed investigated human biological matrices. This
reveals the exemplary robustness of the method.
The cleaned samples are stable for at least one month at
room temperature before derivatization for GC–MS. They were
stable for more than 30 h in derivatized form, ready to be ana-
lyzed in an autosampler. The LOD (15 ng/mL) and the LOQ
(50 ng/mL) meet the requirements of FDA guidelines and the
method meets analytical standards according to ISO 17025.
Therefore, the method is suitable for assessing PHT in different
tissues, including liquor/brain microdialysate at therapeutic
concentrations (100–200 ng/mL). The method might be of
primary interest for research purposes such as toxicity, clinical
trials or PK/PD investigations of patients in critical care with
brain surgery/trauma in which microdialysis is used.
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